Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Buy

Exponential Moving Average

Buy

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Galapagos NV (GLPG)

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/13/2015

Market Cap

1,611,843,042

Shares Outstanding

65,900,000

Weighted SO

65,897,071

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

CTMX --.--%

SPRO --.--%

NLTX --.--%

TIL --.--%

NXTC --.--%

ASMB --.--%

ACHL --.--%

NUVB --.--%

Beta

0.0720

Last Div

0.0000

Range

24.16-42.46

Chg

0.1000

Avg Vol

121270

Mkt Cap

1611843042

Exch

NASDAQ

Country

BE

Phone

32 1 534 29 00

DCF Diff

51.4497

DCF

-25.7097

Div Yield

0.0000

P/S

28.5991

EV Multiple

-16.2088

P/FV

0.5032

Div Yield %

0.0000

P/E

5.1824

PEG

0.0263

Payout

0.0000

Current Ratio

10.0476

Quick Ratio

9.8739

Cash Ratio

0.1435

DSO

723.7632

DIO

211.7335

Op Cycle

935.4967

DPO

428.7600

CCC

506.7367

Gross Margin

-1.1331

Op Margin

-3.6614

Pretax Margin

-0.1810

Net Margin

5.5186

Eff Tax Rate

0.5542

ROA

0.0659

ROE

0.1007

ROCE

-0.0478

NI/EBT

-30.4914

EBT/EBIT

0.0494

EBIT/Rev

-3.6614

Debt Ratio

0.0025

D/E

0.0037

LT Debt/Cap

0.0023

Total Debt/Cap

0.0037

Int Coverage

-84.1148

CF/Debt

-33.5688

Equity Multi

1.4742

Rec Turnover

0.5043

Pay Turnover

0.8513

Inv Turnover

1.7239

FA Turnover

0.3985

Asset Turnover

0.0119

OCF/Share

-5.5388

FCF/Share

-6.8026

Cash/Share

52.0572

OCF/Sales

-7.1277

FCF/OCF

1.2282

CF Coverage

-33.5688

ST Coverage

-88.5046

CapEx Coverage

-4.3828

Div&CapEx Cov

-4.3828

P/BV

0.5032

P/B

0.5032

P/S

28.5991

P/E

5.1824

P/FCF

-3.2670

P/OCF

-4.0124

P/CF

-4.0124

PEG

0.0263

P/S

28.5991

EV Multiple

-16.2088

P/FV

0.5032

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 23, 05:30 Galapagos benoemt Aaron Cox als Chief Financial Officer GlobeNewswire Inc. Jun 23, 05:30 Galapagos Appoints Aaron Cox as Chief Financial Officer GlobeNewswire Inc. Jun 05, 05:00 Planisware expands into Belgium to support the sustained growth of its business in the Benelux region GlobeNewswire Inc. Apr 15, 05:30 Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 GlobeNewswire Inc. Apr 15, 05:30 Galapagos kondigt het vertrek van haar CFO en COO, Thad Huston, aan per 1 augustus 2025 GlobeNewswire Inc. Dec 07, 17:30 Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma GlobeNewswire Inc. Dec 07, 17:30 Galapagos kondigt bemoedigende nieuwe resultaten aan van de lopende fase 1/2-studie van de CD19 CAR T-celtherapie GLPG5101 bij patiënten met recidief/refractair non-Hodgkin lymfoom GlobeNewswire Inc. Jan 02, 01:00 Galapagos tekent overeenkomst om Jyseleca® business over te dragen aan Alfasigma GlobeNewswire Inc. Jan 02, 01:00 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma GlobeNewswire Inc. Jan 02, 01:00 Galapagos tekent overeenkomst om Jyseleca® business over te dragen aan Alfasigma GlobeNewswire Inc. Jan 02, 01:00 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma GlobeNewswire Inc. Jan 02, 01:00 Galapagos tekent overeenkomst om Jyseleca® business over te dragen aan Alfasigma GlobeNewswire Inc. Jan 02, 01:00 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma GlobeNewswire Inc. Jan 02, 01:00 Galapagos tekent overeenkomst om Jyseleca® business over te dragen aan Alfasigma Zacks Investment Research Dec 26, 11:35 Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy GlobeNewswire Inc. Dec 09, 12:00 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 GlobeNewswire Inc. Dec 09, 12:00 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 GlobeNewswire Inc. Dec 09, 12:00 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 GlobeNewswire Inc. Dec 09, 12:00 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 GlobeNewswire Inc. Dec 09, 12:00 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Revenue Product Segmentation